Adagio Therapeutics fetches $336m Series C

Adagio Therapeutics Inc, a developer of best-in-class antibodies to broadly neutralize coronaviruses, has closed $336 million in Series C financing.

Adagio Therapeutics Inc, a developer of best-in-class antibodies to broadly neutralize coronaviruses, has closed $336 million in Series C financing. RA Capital Management led the round.

Source: Press Release